PTC Therapeutics ( (PTCT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PTC Therapeutics’ stock experienced unusual movement due to the FDA’s decision to fast-track the approval process for vatiquinone, a drug aimed at treating Friedrich ataxia, despite a phase 3 study not showing significant benefits. This development led BofA analyst Tazeen Ahmad to upgrade the stock from Underperform to Neutral, recognizing standalone value in the company’s prospects.
More about PTC Therapeutics
YTD Price Performance: 14.41%
Average Trading Volume: 709,328
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.14B
For further insights into PTCT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.